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I. INTRODUCTION
Proteins constitute an important class of biological molecules,
exhibiting a wide range of useful functional attributes. Many proteins
form the basis of valuable commercial products, including
therapeutics, diagnostics, research reagents, genetically modified
organisms and industrial enzymes. In view of their commercial
relevance, it is no surprise that the developers of novel proteins often
seek patent protection for these molecules and the polynucleotides
encoding them.' In recent years, as more protein inventions have
matured into major commercial products, these patents have
increasingly become the subject of enforcement and litigation.
Oftentimes, however, these actions result in the patent being found
invalid and/or not to cover the allegedly infringing product.2 In a
recent article aimed primarily towards the biotechnology community,
Dufresne and Duval surveyed a large number of granted patents
claiming genetic sequences and found the typical approaches to
claiming such sequences to be "heterogeneous and imprecise, which
may lead to questions regarding their validity."
3
Clearly, from the point of view of the patentee, it is critical to
employ a claiming strategy that will result in valid claims and
maximal breadth of coverage. At the same time, the public has an
interest in limiting protein claims to a reasonable scope,
commensurate with an invention's contribution to the field.
Furthermore, a claim reciting a genus of proteins should be
sufficiently definite to adequately apprise third-parties of the metes
1. To obtain a rough measure of the extent to which protein sequences are the subject of
patent claims, on May 19, 2004, the United States Patent and Trademark Office (PTO) database
was searched for claims containing the terms "protein" or "polypeptide" and "sequence." There
were 17,250 patents issued since 1976 that contained these terms. See USPTO, at
http://www.uspto.gov.
2. See, e.g., Chiron Corp. v. Genentech, Inc., 363 F.3d 1247 (Fed. Cir. 2004) (finding
antibody claim invalid for failure to satisfy written description requirement); Noelle v.
Lederman, 355 F.3d 1343 (Fed. Cir. 2004) (finding antibody claim invalid for failure to satisfy
written description requirement); Biogen, Inc. v. Berlex Labs, Inc., 318 F.3d 1132 (Fed. Cir.
2003) (finding patents relating to recombinant production of human interferon not infringed);
Regents of the Univ. of Cal.v. Eli Lilly and Co., 119 F.3d 1559 (Fed. Cir. 1997) (finding claims
to genes encoding insulin invalid for failure to satisfy written description requirement);
Genentech, Inc. v. Wellcome Found Ltd., 29 F.3d 1555 (Fed. Cir. 1994) (finding modified
version of human tPA having several sizable deletions did not infringe claims to human tPA
under the doctrine of equivalents); Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200 (Fed. Cir.
1991) (finding claims to DNA sequence encoding erythropoietin analogs not enabled).
3. Guillaume Dufresne & Manuel Duval, Genetic Sequences: How Are They Patented?,
22 NATURE BIOTECHNOLOGY 231, 231-32 (2004).
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and bounds of the claims. In this article, I propose an approach to
claiming proteins that addresses these issues in a manner that is in
many ways superior to currently prevalent claiming strategies. The
approach involves claiming a genus of related proteins sequences as
defined by a reference sequence and a "similarity score," and is
analogous to the standard technique of claiming proteins in terms of a
reference sequence and percent identity.
I will begin by discussing some specific characteristics of
proteins that make broad claim scope critical to the patentee, while at
the same time rendering it difficult to obtain protein claims that are
both valid and sufficiently broad to preclude design around by trivial
modification. In the past, a number of approaches to claiming broad
genuses of protein sequence have been employed; I will review
several of these approaches and discuss some technical and legal
obstacles with regard to their use. Next, I will describe what I refer to
as the "similarity score" approach to claiming proteins, pointing out
some of its advantages relative to the alternative approaches. Finally,
I will explain how freely available software, such as the widely used
Basic Local Alignment Search Tool, commonly known as BLAST,
can be used to implement this claiming strategy, and provide
examples of the use of BLAST to draft and analyze claims, both with
respect to a potentially infringing sequence or in evaluating a claim
with respect to the prior art.4
II. THE CHALLENGE OF ACHIEVING EFFECTIVE PATENT PROTECTION
FOR PROTEINS
A. Protein Analogs and the Complex Relationship between
Protein Structure and Function
Structurally, a protein can be defined as a biopolymer composed
of one or more chains of amino acids in a specific order, i.e.,
polypeptide chains. 5 In naturally occurring proteins, the order (or
"sequence") of the amino acids is determined by the base sequence of
nucleotides in the gene that codes for the protein.6 For the purpose of
4. The novelty and nonobviousness of an invention are judged against everything
publicly known before the invention, as shown in earlier patents and other published material.
This body of public knowledge is called "prior art." See 35 U.S.C. § 102 (2004), which states,
"A person shall be entitled to a patent unless .... " This language is followed by a series of
definitions.
5. See THOMAS E. CREIGHTON, PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES
Ch. 1, (W.H. Freeman & Co. 1983).
6. See id. Ch. 2.
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this paper, I will focus on single chain proteins and make the
simplifying assumption that all the amino acids that make up a protein
are "standard" amino acids, i.e., selected from the group of twenty
amino acids encoded by the standard genetic code.7 Proteins can be
defined structurally in terms of their "sequence," that is, the sequence
of the amino acids in the polypeptide chain.
In its native state, a protein typically folds to form a complex
three-dimensional structure, with various functional groups of the
amino acids positioned in a manner that enable the protein to perform
its function. 8 It is the protein's sequence that dictates the three-
dimensional structure, and hence the functionality of the protein.9
However, there is some redundancy in this relationship between
sequence and the structure/function of a protein.10 As a consequence,
oftentimes, proteins having similar but non-identical sequences form
substantially equivalent three-dimensional structures and exhibit
substantially identical function." The more similar two sequences
are, the more likely it is that they will be functional equivalents.
However, in many cases substantial variations between sequences are
tolerated without giving rise to any substantial difference in three-
dimensional conformation or function.1 2  In naturally-occurring
proteins, for instance, sequence similarity between two proteins can
be used to infer an evolutionary relationship, i.e., that the proteins
share a common ancestor, and that the sequences have diverged
during the course of evolution.
As a corollary, typically, the sequence of a protein can be altered
by substitutions at one or more amino acid positions without
substantially affecting the protein's three-dimensional structure or
function. Even relatively substantial sequence variations, such as
substitutions at 50% or more of the amino acid positions, or the
introduction of multiple deletions or insertions in the sequence, can at
times be accommodated without substantially altering function.
13
7. Naturally occurring proteins often include other amino acids, which can be encoded
by alternate genetic codes or the result of post-translational modifications. Protein claims
typically do not address this issue. For the purpose of not overly complicating this article, I will
disregard these non-standard amino acids, although generally the rationale behind the proposed
claiming strategy would apply even if non-standard amino acids were taken into account.
8. See CREIGHTON, supra note 5.
9. Id.
10. Id.
11. See id. Ch. 6.
12. Id.
13. Id.; BIOINFORMATICS FOR GENETICISTS Ch. 14 (Michael R. Barnes & Ian C. Gray
eds., John Wiley & Sons, Ltd. 2003).
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Bearing in mind that a typical protein comprises hundreds of amino
acids, that the standard genetic code allows for nineteen possible
amino acid substitutions at each position, and that typically a variety
of substitutions, insertions and/or deletions can be accommodated
without substantially altering protein function, it is evident that a
genus of related proteins sharing similar sequence and conserved
function (referred to herein as "analogs," or "functional variants" of
one another) can be astronomical in size. This has important
ramifications for the patenting of novel and commercially relevant
proteins. Unless protein claims encompass these analogs, it can be
relatively straightforward for a competitor to design around a claim
simply by generating and commercializing one of these analogs.'
4
This can be accomplished, e.g., by isolating a naturally occurring
homolog of the protein, or by engineering a non-naturally occurring
variant using any of a wide range of recombinant techniques. 5 For
example, a straight-forward approach to designing around a patent
claiming a specific protein sequence would be to make a number of
point mutants of the protein and screen these mutants to identify one
that retains the desired function. Alternatively, a more sophisticated
approach, such as DNA shuffling or molecular directed evolution,
could be used to generate a variant having a large number of
substitutions while still retaining the desired function.
14. See, e.g., Schering Corp. v. Amgen, Inc., 222 F.3d. 1347, 1350-52 (Fed. Cir. 2000).
Amgen avoided Schering's patent covering interferon-a by commercializing a consensus
interferon-a, which Amgen generated synthetically after reviewing the sequences of all known
interferon-u subtypes. The consensus sequence contains, at each position, an amino acid present
in one or more known interferon-a subtype, but does not duplicate the amino acid sequence of
any single interferon-a subtype and thus, does not correspond to any naturally occurring
interferon subtype. Id.; see also, Antony L. Ryan & Roger G. Brooks, Innovation vs. Evasion:
Clarifying Patent Rights in Second-Generation Genes and Proteins, 17 BERKELEY TECH. L.J.
1265, 1276-78 (2002).
15. This was alluded to in Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956 (Fed. Cir.
2002) (Enzo II), wherein an expert testified that "astronomical" numbers of mutated variations
of the deposited sequence would fall within the scope of the claims, and that such broad claim
scope is necessary to adequately protect Enzo's invention from copyists who could otherwise
make a minor change to the sequence and thereby avoid infringement while still exploiting the
benefits of Enzo's invention. Id. at 966. Techniques for generating protein variants include site-
directed mutagenesis and directed evolution methodologies. See, e.g., Richard Fox et al.,
Optimizing the Search Algorithm for Protein Engineering by Directed Evolution, 16 PROTEIN
ENGINEERING 589 (2003); Claes Gustafsson et al., Putting Engineering Back into Protein
Engineering: Bioinformatic Approaches to Catalyst Design, 14 BIOTECHNOLOGY 366 (2003);
Jeremy Minshull & Willem PC Stemmer, Protein Evolution by Molecular Breeding, 3
CHEMICAL BIOLOGY 284 (1999); Phillip A. Patten et al., Application of DNA Shuffling to
Pharmaceuticals and Vaccines, 8 BIOTECHNOLOGY 724 (1997).
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In practice, there are a number of non-patent barriers to entry
that might come into play in this scenario, e.g., in the case of a
regulated product, such as a human therapeutic, the alteration in
sequence might raise new regulatory issues that have already been
resolved for the original molecule. 16 Nevertheless, in many instances,
the protection provided by a patent that only covers a single sequence
would be of very little commercial value if these other barriers to
entry could be overcome. This would particularly be the case for
proteins that are not subject to the strict regulatory scrutiny of
agencies such as the FDA, e.g., a recombinant enzyme being
commercialized for industrial purposes or for use as research
reagents.' 7 Since a user of an industrial enzyme is only interested in
exploiting the catalytic function of the enzyme, it would generally be
straightforward for a competitor to engineer and commercialize a
functional variant that avoids a narrowly claimed patent without
raising any attendant regulatory issues.
In principle, an inventor of a novel protein could attempt to
identify specific sequences corresponding to functional variants of the
protein, and explicitly recite these in a claim. However, as discussed
above, the number of potential functional variants would be
astronomical, so even a claim listing many thousands of sequences
would cover only a tiny fraction. To avoid literal infringement of the
claim, a competitor would need merely to identify and commercialize
one of the many analogs that are not identified in the claim.
B. Application of the Doctrine of Equivalents to Protein Claims
Of course, to some extent the doctrine of equivalents is available
to expand claim coverage to include analogs incorporating
"insubstantial" changes.1 8  There are a number of cases where the
16. Lester M. Crawford, D.V.M., Ph.D., Acting Commissioner of Food and Drugs,
Department of Health and Human Services, The Law of Biologic Medicine, Statement Before
the Committee on the Judiciary/U.S. Senate (June 23, 204), at
http://www.hhs.gov/asl/testify/tO4O623.html (discussing the regulatory hurdles that must be
traversed in order to secure FDA approval for follow-on versions of protein-based drugs).
17. For examples of such products, including proteases that are used as additives in
laundry detergents, see http://www.genencor.com/wt/gcor/clean, (last visited Sept. 25, 2004),
and DNA polymerases used in PCR, see http://www.appliedbiosystems.com/catalog, (last
visited Sept. 25, 2004).
18. Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 US 722, 731-33 (2002)
(stating that under the doctrine of equivalents, "[t]he scope of a patent is not limited to its literal
terms but instead embraces all equivalents to the claims described").
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doctrine of equivalents has been applied to protein claims. 9
Nevertheless, while the doctrine is clearly available in some cases to
expand the scope of protein claims, it is hard to predict the extent of
sequence variation that would be permitted before the difference
between the claimed and accused sequences becomes so substantial as
to avoid the doctrine. The doctrine should be available to prevent a
competitor from avoiding a patent simply by introducing a single
point mutation of negligible functional significance. 20 However, what
about the case where an accused analog incorporates multiple
changes, perhaps resulting in a relatively minor change in three-
dimensional structure or some alteration in function?
Most proteins possess multiple functions, so a determination that
a protein's function has been substantially altered would, to some
extent, depend upon how the protein's function or functions are
defined. For example, what if alterations to a protein's sequence
change a commercially irrelevant function without altering what are
perceived to be the commercially relevant functions of the protein, or
the alterations merely change an ancillary property such as pH
dependence or temperature stability? What if the alterations cause
some change in the magnitude of a functional characteristic, but the
change is commercially insubstantial? It is an open question as to
what extent the doctrine of equivalents would be available to the
patentee in situations such as these.
As illustrated by the Festo decisions and other recent Federal
Circuit case law, the trend is clearly towards a severely restricted
application of the doctrine of equivalents. 2' In light of this trend, and
the overall uncertainty surrounding this area of the law, the prudent
practitioner will, to the extent possible, seek broad literal coverage
rather than rely upon the doctrine of equivalents to ensnare infringers.
C. Claims Defining Proteins Solely in Terms of Function are
Generally not Valid
In the early days of biotechnology patenting, claims often
defined proteins simply in terms of function. Sometimes this was all
that was known about the protein at the time the application was filed,
particularly in cases where the DNA encoding the protein had yet to
19. See, e.g., Amgen, Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313 (Fed. Cir.
2003); Genentech, Inc. v. Wellcome Found Ltd., 29 F.3d 1555 (Fed. Cir. 1994).
20. Genentech, Inc., 29 F.3d at 1566-67.
21. Festo Corp. v, Shoketsu Kinzoku Kogyo Kabushiki Co., 234 F.3d 558 (Fed. Cir.
2000), vacated by 535 U.S. 722 (2002), remanded to 344 F.3d 1359 (Fed. Cir. 2003).
[Vol. 21
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be isolated. However, functional definitions also result in broad
literal coverage, which on its face encompasses functional variants of
the claimed protein. If the only limitation is function, then in
principle the claim should encompass any and all variants that retain
the desired function. Unfortunately for the patentee, these claims
have not fared well in the courts, and the overwhelming trend is
clearly toward a requirement of some sort of structural definition of
the protein, or at least a physical description of the protein that goes
beyond mere functional characterization.22
For example, in Amgen, Inc. v. Chugai Pharmaceutical Co.
2 1
claims reciting a DNA sequence encoding a protein having an amino
acid sequence "sufficiently duplicative" of erythropoietin (EPO) to
possess EPO's biological property of causing an increased production
of red blood cells were found invalid for failure to enable 24 the full
scope of the claims.2 ' The court cited the "manifold possibilities" for
changes to the structure of EPO "with attendant uncertainty as to what
utility will be possessed by these analogs," and the failure of Amgen
to identify "structural requirements for producing compounds with
EPO-like activity." 26
In Ex parte Maizel,27 a patent application disclosed the amino
acid sequence of a human B-cell growth factor. Claims reciting a
DNA vector encoding a protein having the disclosed amino acid
sequence or a "biologically functional equivalent thereof' were found
invalid for lack of enablement. 28  The Board of Patent Appeals
22. Antibodies, which are themselves proteins, apparently represent an exception to this
rule. For example, in Noelle v. Lederman, 355 F.3d 1343, 1349 (Fed. Cir. 2004), the court
stated that
based on our past precedent, as long as an applicant has disclosed a "fully
characterized antigen," either by its structure, formula, chemical name, or
physical properties, or by depositing the protein in a public depository, the
applicant can then claim an antibody by its binding affinity to that described
antigen.
Id.
23. 927 F.3d 1200 (Fed. Cir. 1991).
24. The enablement requirement refers to the requirement of 35 U.S.C. § 112, 1, that the
specification provide a description of how to make and use the invention without "undue
experimentation." See also, In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988).
25. In many of the cases discussed herein, the claims at issue pertain specifically to DNA
molecules encoding the functionally defined proteins. However, the rationale behind the
decisions should apply equally to claims directed to proteins per se. Indeed, the claims typically
define the claimed DNA in terms of the encoded protein, and the determination of invalidity
hinges upon issues relating to adequate disclosure of the protein.
26. Amgen, 927 F.2d at 1214.
27. 27 U.S.P.Q. 2d (BNA) 1662 (B. Pat. App. Interferences 1992).
28. Id. at 1665.
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analogized the rejected claims to a single means claims, and opined
that the "problem with the phrase 'biologically functional equivalent
thereof is that it covers any conceivable means, i.e., cell or DNA,
which achieves the stated biological result while the specification
discloses, at most, only a specific DNA segment known to the
inventor.,
29
In Fiers v. Revel,30 an interference count which purported to
cover all DNA molecules coding for beta interferon was found not to
comply with the written description requirement,31 for such an
invention "requires a precise definition, such as by structure, formula,
chemical name or physical properties," not a mere wish or plan for
obtaining the claimed invention.32 The court held that knowledge of
the chemical nature of the DNA is a prerequisite to an adequate
written description (and this requirement can be inferred to apply to
the description of other biological molecules such as proteins).33
Particularly compelling support for the proposition that at least
some definition of structure is needed for a valid protein genus claim
can be found in Regents of the University of California v. Eli Lilly and
Co.34 In that decision, claims directed to genes encoding mammalian
insulin were found to be inadequately supported by the description of
rat insulin cDNA, and hence invalid for failure to satisfy the written
description requirement.35  The court distinguished the rejected
claiming strategy from the accepted practice of describing a broad
chemical genus by means of a generic formula.36 The rejected claims
described the genus in terms of its function, and did not define any
structural features commonly possessed by members of the genus that
distinguish them from others.37
The Eli Lilly decision has been controversial, and is viewed by
some as a novel and ill-advised interpretation of the written
description requirement. 38  Nevertheless, it is widely cited as
29. Id.
30. 984 F.2d 1164, 1171 (Fed. Cir. 1993).
31. 35 U.S.C. § 112, 1 requires that the specification shall contain a written description
of the invention. See, e.g., Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1560 (Fed. Cir. 1991).
32. Fiers, 984 F.2d at 1171.
33. Id.
34. 119 F.3d 1559, 1566 (Fed. Cir. 1997).
35. Id. at 1568-69.
36. Id.
37. Id.
38. Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956, 976, 979-81 (Fed. Cir. 2002)
(Rader, J., dissenting).
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precedent, particularly in cases pertaining to biological molecules and
other chemical entities.39 Indeed, Eli Lilly caused the U.S. Patent and
Trademark Office (PTO) to reevaluate its own application of the
written description requirement. In response to the decision, they
published "Guidelines for Examination of Patent Applications Under
the 35 U.S.C. 112, 1 'Written Description' Requirement'40 and a
"Synopsis of Application of Written Description Guidelines"
(referred to herein as the "Guidelines"). 4' The Guidelines apply the
written description requirement, as articulated in Eli Lilly, to a
number of hypothetical claiming scenarios, many involving proteins
and other biological inventions. Interestingly, while the Guidelines
are the product of an administrative agency, they have been relied
upon in a number of Federal Circuit decisions and have to some
extent taken on the mantle of de facto judicial precedent.42
For example, in Enzo II, the Federal Circuit took judicial notice
of the Guidelines, stating that the DNA invention at issue would be
valid if it complied with the written description requirement as
interpreted by the Guidelines, and directing the lower court on
remand to determine if the claimed subject matter was adequately
described in a manner consistent with the PTO guidelines.43  The
Guidelines were cited for the proposition that a biological molecule
can be claimed in terms of function only when "coupled with a known
or disclosed correlation between [that] function and [a] structure" that
is sufficiently known or disclosed.44
More recently, in Noelle v. Lederman,45 the Federal Circuit
characterized an example in the Guidelines directed to a hypothetical
antibody claim as precedent, and relied upon that example to find the
claim at issue invalid for failure to comply with the written
description requirement.46 The example was deemed precedent based
on it having been mentioned in the Enzo II decision. However, the
biological molecules at issue in Enzo II were nucleotide sequences,
39. See, e.g., id. at 964-65; Noelle v. Lederman, 355 F.3d 1343 (Fed. Cir. 2004); Univ. of
Rochester v. G.D. Searle & Co., 358 F.3d 916 (Fed. Cir. 2004); Chiron Corp. v. Genentech,
Inc., 363 F.3d 1247 (Fed. Cir. 2004).
40. Guidelines for Examination of Patent Applications Under the 35 U.S.C. § 112, 1,
"Written Description" Requirement, 66 Fed. Reg. 1099 (Jan. 5, 2001).
41. See Synopsis ofApplication of Written Description Guidelines, at
http://www.uspto.gov/web/menu/written.pdf (last visited May 25, 2004).
42. See Enzo, 323 F.3d 956; Noelle, 355 F.3d 1343.
43. Enzo, 323 F.3d at 967.
44. Id at 964 (emphasis omitted).
45. Noelle, 355 F.3d 1343.
46. ld at 1349.
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not antibodies or even proteins. In fact, Enzo II only referred to the
antibody example in a single sentence, and merely as an example of
the PTO's approach to written description analysis.47 Holding that the
antibody example from the Guidelines is "precedent" suggests that at
this point the court might consider the entire Guidelines to constitute
precedential authority.
The Guidelines themselves provide some guidance as to the
degree to which specific sequence information must be provided in
order to satisfy the written description requirement. For instance, in
Example 11 of the Guidelines, a claim to "[a]n isolated allele of [a
disclosed DNA sequence]" is found to be invalid for a number of
reasons. 48 For one reason, there is no description of the actual
sequence variations that might exist in nature. In addition, the genus
would include members that would be expected to have widely
divergent function, i.e., the structure and function of one allele does
not provide guidance to the structure and function of others.4 9
In Example 13 of the Guidelines, a claim to an "isolated variant
of [a protein having a disclosed sequence]" is found to be invalid.5°
The rationale behind this finding includes the failure of the
specification and claims to indicate distinguishing attributes shared by
members of the genus, i.e., the failure to identify structural features
that could distinguish compounds in the genus from others in the
protein class, and failure to place any limit on the number of amino
acids substitutions, deletions, insertions and/or additions that could be
made in a variant.
5 1
However, in Example 14 of the Guidelines, a claim to variants of
a disclosed protein was found to be valid when the claim was limited
to variant sequences that are at least 95% identical to the disclosed
sequence and are able to catalyze the reaction A -- B (a functional
attribute of the disclosed sequence).52 The Guidelines' analysis of the
example found that procedures for making variants which have 95%
identity and which retain the functional activity are conventional in
the art. It also found that there was no substantial variation amongst
members of the genus since all the variants must possess the specified
catalytic activity and must have at least 95% identity to the reference
47. Enzo, 323 F.3d at 964.
48. See Synopsis ofApplication of Written Description Guidelines, supra note 41, at 41.
49. Id.
50. Id. at 50.
51. Id.
52. Idat 41.
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sequence. 3 There is no indication of how the 95% identity threshold
was arrived at, nor as to how low the percent identity term could be
varied without resulting in an overly broad and invalid claim.
To summarize the case law and the PTO's interpretation of that
case law, Section 112 clearly requires more than a mere functional
definition of a genus of proteins.54 While it is possible to claim a
genus of protein variants sharing similar sequences and common
functionality, it is insufficient to merely recite a specific sequence and
claim it and its functional variants. Rather, the degree of acceptable
sequence variations should be specifically recited, so as to clearly
delineate the metes and bounds of the claim in terms of structure, e.g.,
the percent identity claim of Example 14 in the Guidelines.
Moreover, the sequence definition must to some extent be
predictive of conserved function, though it need not be exactly
predictive of function. For example, in Example 14, the 95% identity
limitation would certainly encompass a large number of non-
functional mutants of the disclosed protein. Nevertheless, 95%
identity is predictive of function in the sense that it is much more
likely that a sequence that is 95% identical to the disclosed protein
will share a common function than would a randomly generated
sequence. For that matter, it is more likely that a 95% identical
sequence will share the function than a similar sequence having a
lower percent identity, e.g., 90% identity. In the Guidelines this
principle is expressed in terms of it being "conventional in the art to
find functionally active variants sharing 95% identity." Implicitly,
there must be a point where the percent identity limitation becomes so
low that it would no longer be "conventional" to find variants at that
level of percent identity which retain the activity, and/or at which
point the degree of sequence variation would constitute "substantial
variation." At that point, the claim would presumably fail to comply
with the written description requirement.
As a corollary, the more predictive the sequence definition is of
conserved function, the more likely it is that the claim will satisfy the
written description requirement.5 5  Consider the 95% identity
limitation from the Guidelines. For a protein sequence of typical
length, the number of possible sequence variants that would share
53. Id.
54. 35 U.S.C. § 112, 1 (2004).
55. See David E. Huizenga, Comment, Protein Variants: A Study on the Differing
Standards for Biotechnology Patents in the United States and Europe, 13 EMORY INT'L L. REV.
629, 655-66, (1999) (noting that predictability was a central issue in Amgen v. Chugai, and that
"[p]rotein variant claims are particularly susceptible to the 'predictability' sword")
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95% identity is enormous. Of this genus of molecules, a significant
percentage would retain the function, i.e., the limitation is to some
extent predictive of conserved function. However, consider the same
claim except that the percent identity limitation has been decreased to
20% identity. The number of potential variants sharing 20% identity
would be much larger than the 95% identity group, because there are
vastly more possibilities for varying the sequence. However, only a
vanishingly small number of these variants would be expected to
retain the function. It would likely require screening an inordinate
number of these variants to find a functional analog, i.e., identifying
such a variant would no longer be "conventional in the art." Under
the Guidelines, this large variation in sequence would likely be
considered substantial, and the claim not to be in compliance with the
written description requirement (nor the enablement requirement, to
the extent that the amount of screening required constitutes undue
experimentation) .56
Let us assume that for a particular protein, the 95% identity
limitation will satisfy the written description requirement while the
20% identity limitation will not. We must conclude that there is some
threshold between 20% and 95% identity that must be exceeded in
order for the claim to be valid. We have little guidance as to the exact
magnitude of the threshold, but clearly it is based on the extent to
which the percent identity limitation is predictive of homology and
conserved function. This imposes a fundamental limitation on the
breadth of claims of this type, since the size of the claimed genus is
inversely proportional to the magnitude of the percent identity
limitation. Clearly, the objective should be to employ a sequence
limitation that covers the broadest range of functional sequence
variants while including a minimal number of non-functional variants.
This objective is best realized by using a sequence limitation that is
maximally predictive of conserved function. The similarity score
approach presented in this article approaches that ideal.
D. Defining a Protein Genus in Terms of Percent Identity
Before delving into the similarity score approach, let us review
the more conventional percent identity approach to claiming a genus
of proteins. Many thousand of examples of such claims appear in
issued U.S. patents.57 For example, see claim 15 of U.S. Patent No.
6,657,047 (the "'047 patent"):
56. 35 U.S.C. § 112 (2004).
57. See USPTO patent database, at http://www.uspto.gov.
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An isolated protein comprising an amino acid sequence 80% or
more identical to a polypeptide encoded by amino acid residues 1
to 385 of SEQ ID NO:2.55
Claims in this format generally recite a "reference sequence"
(e.g., amino acid residues I to 385 of SEQ ID NO:2) and a specified
percent identity (e.g., 80% or more identical), thereby identifying a
genus of polypeptides sharing some minimal threshold of sequence
identity with one another. Most patent applications containing
percent identity claims will include in the specification some
definition of the term "identical." A typical definition, such as that
provided in the '047 patent, will specify that the percent identity
between a reference sequence and a query sequence (i.e., a sequence
being analyzed to determine whether it falls within the scope of the
claim) is determined by aligning the sequences so that the highest
order match is obtained, and comparing the aligned amino acids. The
number of exact matches as a percent of the total number of amino
acids in the reference sequence is determined, and this is the percent
identity of the two sequences. 59 The determination is illustrated
below in Example 1, where two short ten-amino-acid peptides are
aligned.60 Note that the sequences differ only at the fourth and sixth
amino acid positions. Using the percent identity approach, we would
say that since eight out of the ten positions are identical the peptides
are 80% identical.
Example 1
MG E T Y F P L S A
I I I I I I I I
MGE S Y T P L S A
Note that accurate scoring is dependent upon the proper
alignment of the sequences. Though often not explicitly stated, the
logical definition of the appropriate alignment, including positioning
of gaps, should be the alignment that results in the highest percent
identity between the sequences. For very similar sequences,
alignment is trivial. However, for more distantly related sequences,
particularly when there are deletions in one or both of the sequences,
the alignment is not so straightforward. Patent specifications
58. U.S. Patent No. 6,657,047 (issued Dec. 2, 2003).
59. See U.S. Patent No. 6,657,047, col. 3, 1. 60 to col. 4, 1. 63 (issued Dec. 2, 2003).
60. Throughout this article the standard single-letter symbols for amino acids are used.
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typically include references to algorithms and/or computer programs
for performing the alignment.61
To my knowledge, the validity of a percent identity claim has not
been addressed in a reported judicial decision. However, as discussed
above, the approach has been sanctioned by the PTO in the
Guidelines, and the Federal Circuit has shown a marked deference to
these Guidelines. Therefore, it is not unlikely that the Federal Circuit
would look to the Guidelines when assessing the validity of a percent
identity claim.
Note that the claim from the '047 patent does not include a
functional limitation. Protein genus claims lacking a functional
limitation will almost certainly encompass a large number of non-
functional variants, because there are invariably amino acid positions
that cannot be altered without disrupting function.62 When amino
acids are altered at multiple positions in a sequence the likelihood of
an impact on function increases, e.g., changing up to 20% of the
residues in a protein (as permitted by an 80% identity claim) would in
most cases result in an impaired-function mutant. In general, the
lower the magnitude of the percent identity limitation (i.e., the
broader the claim) the higher percentage of non-functional variants
predicted to fall within the bounds of the claim. This in turn raises
the issue of utility, since a polypeptide lacking any known functional
activity would likely fail to satisfy the utility requirement. 63 While
the inadvertent recitation of some non-functional species does not
necessarily invalidate a genus claim, there could be a point where an
excessive number of non-functional species raises validity issues,
particularly where the specification supplies no structural guidance to
distinguish functional from non-functional species.
64
61. U.S. Patent No. 6,657,047 col. 3, 1. 60 to col. 4, 1.24 (issued Dec. 2, 2003).
62. A classic example would be the family of proteases referred to as the serine proteases
(e.g., subtilisin), wherein it is known that any mutation that disrupts the amino acids that make
up the enzyme's "catalytic triad" will severely disrupt the catalytic ability of the enzyme.
63. The utility requirement arises from 35 U.S.C. § 101, which has been interpreted as
requiring that in order to be patentable an invention must have a substantial practical utility.
See, e.g., Brenner v. Manson, 383 U.S. 519 (1966); In re Ziegler, 992 F.2d 1197 (Fed. Cir.
1993). A deficiency in utility under 35 U.S.C. § 101 also creates a deficiency under 35 U.S.C. §
112, 1. See In re Brana, 51 F.3d 1560 (Fed. Cir. 1995).
64. See, e.g., Amgen, Inc. v. Chugai Pharm. Co., 927 F.3d 1200, 1214 (Fed. Cir. 1991)
(finding claims non-enabled in view of the "manifold possibilities" for changes to the structure
of EPO "with attendant uncertainty as to what utility will be possessed by these analogs," and
the failure of Amgen to identify "structural requirements for producing compounds with EPO-
like activity").
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In most percent identity claims the issue of non-functional
species is addressed by means of a functional limitation, which
explicitly limits the claim to functional variants. Example 14 of the
Guidelines, or claim 1 of U.S. Patent No. 6,667,391 states:
An isolated polypeptide comprising an amino acid sequence that is
a least 99% identical to SEQ ID NO: 23, wherein the polypeptide
exhibits stem cell growth factor activity.
65
This claim format is the currently preferred approach to claiming
a genus of structurally related proteins. 66  The percent identity
limitation provides a definite structural recitation of the claimed
molecules, and the functional limitation explicitly excludes molecules
lacking utility from the claimed genus. For the remainder of this
article, the term "percent identity claim" will refer to a claim that
includes percent identity and functional limitations.
As discussed above, the rationale underlying the percent identity
approach is that the percent identity between two sequences is
predictive of conserved function and sequence homology.67 But what
exactly is the relationship between percent identity, conservation of
function, and sequence homology? The term "percent homology" is
often used, but this terminology tends to confuse two distinct issues.
Homology is a biological term denoting that two protein sequences
have evolved from a common ancestor. Depending on the
evolutionary distance between the sequences, the number of amino
acid differences between homologous proteins can be great, at some
point rendering it difficult or impossible to discern the common
ancestry of the sequences.
Thus, strictly speaking, the term "percent homology" is a
misnomer; either two proteins can trace their ancestry back to a
common sequence, or they cannot. However, percent identity is a
predictor of homology; in general, the extent of percent identity
between two sequences roughly correlates with the probability that
the sequences are homologous. This is premised on that fact that, in
view of the vast number of possible amino acid sequences, it is
extremely unlikely that two different protein sequences sharing
substantial percent identity would have arisen independently during
the course of evolution, and hence, they must in all likelihood be
65. U.S. Patent No. 6,667,391 (issued Dec. 23, 2003).
66. See USPTO patent database, at http://www.uspto.gov, for examples of recent patent
and published patent applications.
67. See Synopsis ofApplication of Written Description Guidelines, supra note 41, at 46.
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68descended from the same common ancestor. As a corollary, it is
likely that homologous proteins will share function, because to the
extent the function confers some advantage upon an organism, there
will be evolutionary pressure to maintain that function, i.e., loss-of-
function mutations tend to be selected against.69 Hence, we have the
relationship between homology, percent identity and conserved
function in naturally occurring proteins: proteins sharing high percent
identity are likely homologous, and they share conserved function
because otherwise they would not have been retained by an organism
during the course of evolution.
Note that this relationship breaks down to some extent in the
case of non-naturally occurring proteins, i.e., synthetic sequences
generated using recombinant technology. For example, the genus of
all possible protein sequences sharing 80% identity with a given
reference sequence is astronomical, and it is likely that only a small
fraction of these actually exist in nature as homologs of the reference
sequence. 70 However, in principle any of the sequences falling within
the genus could be synthesized using recombinant technology.
Hence, unless the claimed genus is limited to naturally occurring
proteins, it will encompass a vast number of sequences that are
technically not homologs. Patent claims typically lack any such
limitation, although in some cases it might be implicit, e.g., in the
case of a percent identity claim that lacks a functional limitation.
Furthermore, a percent identity delimited genus including
synthetic variants will generally include a large number of non-
functional proteins, because without the constraint of evolutionary
pressure there is no mechanism to select against loss of function. 7' At
the same time, the genus will include many synthetic variants that
68. See CREIGHTON, supra note 5, Ch. 12.
69. STRUCTURAL BIOINFORMATICS Ch. 12, (Philip E. Bourne & Helge Weissig eds.,
Wiley-Lis, Inc. 2003).
70. For example, consider a typical protein 300 amino acids in length. Assuming 20
possible amino acid residues, there are 19 possible changes at each of the 300 positions. The
equation to calculate the number of possible 300 amino acid sequences sharing 80% identity is
(19 x 300) + (19 x 300)(19 x 299) + (19 x 300)(19 x 299)(19 x 298) +... ,continuing up to the
point where the equation includes the term containing (19 x 240), i.e., 240 is 80% of 300). The
solution to this equation is 1.8 x 10226, i.e., there are 1.8 x 10226 possible variants sharing 80%
identity with any given 300 amino acid protein. On the other hand, the number of different
species of living organisms has been estimated at from 106 to 108, a miniscule fraction of the
total number of possible 80% identical variants. See James Cotton, Re: How Many Different
Living Organisms Are There Today?, MadSci Network, at
http://wwwmadsci.org/posts/archives/un2000/959840635.Zor.html (last visited Sept. 25,
2004).
71. STRUCTURAL BIOINFORMATICS, supra note 69.
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retain function but that are not "homologs" in the biological sense
since they are not literally descended from a common ancestor. As
discussed above, typically there are many ways in which a sequence
can be synthetically altered without disrupting activity; indeed, in
many cases the function can actually be improved.72  As a
consequence, percent identity is much less effective at predicting
conserved function when the claim is not limited to naturally
occurring proteins. The generation of synthetic proteins, often times
with novel and/or improved function, is a very active field of
endeavor, with a number of companies seeking to commercialize such
proteins.73 Furthermore, the generation of synthetic analogs would be
an obvious tactic for avoiding claims directed to a product based on a
naturally occurring protein sequence. Clearly, the prudent practitioner
will do well to draft protein genus claims with these potential
synthetic variants in mind.
III. THE SIMILARITY SCORE APPROACH TO CLAIMING PROTEIN
GENUSES
At this point, I will present and explain the similarity score
approach to claiming a protein genus. Compared to percent identity
claims, the similarity score approach has the following advantages:
(1) it better accounts for the fact that not all amino acid substitutions
are functionally equivalent, some being more conservative than
others; (2) it better accounts for insertions and deletions, which are
typically treated no differently than substitutions in percent identity
approaches; (3) it takes into account the length and structural
complexity of a sequence; (4) it is particularly well suited for use with
synthetic, non-naturally occurring sequences; and (5) it is more
consistent with the manner in which scientists evaluate related
sequences for homology and/or conserved function. Furthermore, the
scope of similarity score claims is at least as definite and
unambiguous as a percent identity claim. The determination of
whether a sequence of interest falls within the claimed genus can be
accomplished in a straightforward manner using simple arithmetic,
with or without the aid of a computer. The software needed to
automate the determination is freely available over the Internet, e.g.,
72. See supra note 15.
73. Examples include Maxygen, Inc. (Redwood City, CA), Applied Molecular Evolution,
Inc. (San Diego, CA) and Diversa Corporation (San Diego, CA).
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the BLAST algorithms at the National Center for Biotechnology
Information (NCBI) website.7 4
A. Comparing Protein Sequences in Terms of Similarity Score
To begin, I will demonstrate how a similarity score is determined
for a pair of aligned sequences. I will then work through a number of
examples, pointing out the advantages of the approach compared to
percent identity. Finally, I will demonstrate how the BLAST
alignment tool can be used to draft and analyze similarity score
claims.
Similarity scores for aligned sequences are widely used in a
number of computer-implemented approaches to protein sequence
analysis, including the widely used BLAST sequence alignment
tool.75 Basically, a score for two aligned sequences is determined by
means of a twenty-by-twenty scoring matrix, representing the 210
possible pairings of the twenty amino acids encoded by the standard
genetic code. A number of different scoring matrices have been
derived, many having attributes that make them particularly well
suited for analyzing particular types of sequences and alignments.76
In the following examples, I will employ exclusively the BLOSUM62
matrix (see Figure 1 below), a good general-purpose scoring matrix
and the default used in the NCBI version of BLAST.7 7 The pairings
represent amino acids that line up with one another in a given
sequence alignment. The score for any pair can be positive or
negative, with identical amino acid pairs (representing a position in
the alignment that is conserved between the two sequences) having
the highest scores, followed by those that share some degree of
homology (e.g., leucine and isoleucine), with the more non-
conservative pairings having the most negative scores. The more
positive the score, the more similar the sequences and the more likely
it is that they are homologous and/or share a conserved function.
78
74. A general overview of scoring matrices and the BLAST sequence alignment tools are
provided at the National Center for Biotechnology Information (NCBI) BLAST website, at
http://www.ncbi.nlm.nih.gov/BLAST (last visited May 25, 2004). The BLOSUM62 matrix is
described in Steven Henikoff & Jorja G. Henikoff, Amino Acid Substitution Matrices from
Protein Blocks, 89 PROC. NAT'L ACAD. SC. 10915 (1992), available at
http://www.pnas.org/cgi/reprint/89/22/10915.pdf (last visited Oct. 5, 2004).
75. NCBI BLAST, supra note 74.
76. Id.
77. Id.
78. Id.
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Consider the case of two short sequences, where there is no gap
in either of the aligned sequences throughout the length of the
sequences being compared. Example 2 is a fifteen amino acid
sequence (the N-terminal of maltoporin precursor, Accession No.
NP_807741.1) aligned with itself, i.e., an alignment of 100% identical
sequences.
Example 2
MM I T L RK L P LAVAVA
MM I T L RKL P LAVAVA
5 5 4 5 4 5 5 4 7 4 4 4 4 4 4 (68)
Underneath each amino acid is the score for that particular
pairing, obtained by finding the number at the intersection of the
amino acids on the BLOSUM62 matrix (Fig. 1). The score for the
alignment is sixty-eight, the sum of the fifteen individual scores.
Note that a score of sixty-eight is the highest possible score that any
amino acid sequence could generate when aligned with this particular
fifteen amino acid segment, because the score for any non-identical
pair is always lower than the score for an identical pairing.
Example 3 is another fifteen amino acid sequence taken from
maltoporin precursor, again aligned with itself.
Example 3
RF Y Q RH DV HM I D F Y Y
R F Y QRH DVHM I D F Y Y
5 6 7 5 5 8 6 4 8 5 4 6 6 7 7 (89)
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Figure 1
BLOSUM62 Matrix
A 4
R -1 5
N -2 0 6
D -2 -2 1 6
C 0 -3 -3 -3 9
Q -1 1 0 0 -3 5
E -1 0 0 2 -4 2 5
G 0 -2 0 -1 -3 -2 -2 6
H -2 0 1 -1 -3 0 0 -2 8
1 -1 -3 -3 -3 -1 -3 -3 -4 -3 4
L -t -2 -3 -4 -1 -2 -3 -4 -3 2 4
K -1 2 0 -1 -3 1 1 -2 -1 -3 -2 5
M -1 -1 -2 -3 -1 0 -2 -3 -2 1 2 -1 5
F -2 -3 -3 -3 -2 -3 -3 -3 -1 0 0 -3 0 6
P -1 -2 -2 -1 -3 -1 -1 -2 -2 -3 -3 -1 -2 -4 7
S 1 -1 1 0 -1 0 0 0 -1 -2 -2 0 -1 -2 -1 4
T 0 -1 0 -1 -1 -1 -1 -2 -2 -1 -1 -1 -1 -2 -1 1 5
W -3 -3 -4 -4 -2 -2 -3 -2 -2 -3 -2 -3 -1 1 -4 -3 -2 11
Y -2 -2 -2 -3 -2 -1 -2 -3 2 -1 -1 -2 -1 3 -3 -2 -2 2 7
V 0 -3 -3 -3 -1 -2 -2 -3 -3 3 1 -2 1 -1 -2 -2 0 -3 -1 4
A R N D C Q E G H I L K M F P S T W Y V
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Note that this alignment generates a score of eighty-nine
(twenty-one points higher than the score from Example 2). This
reflects the facts that this sequence includes residues that generate
higher score for identical pairings, e.g., H, Y, F and D. Residues that
are the most chemically and/or structurally unique, and/or that appear
less frequently in proteins, such as W, C, H, P and Y produce the
highest scores for identical matches (eleven, nine, eight, seven and
seven, respectively), because the fact that they are conserved between
two sequences is a more significant indication of homology than the
conservation of more commonly occurring and/or more easily
substituted for amino acids, such as A, I, L, S and V (all generating
score of four). Note that the theoretical maximum score for a fifteen
amino acid alignment is 165 (for a sequence of fifteen consecutive
Ws), and the theoretical minimum score is sixty (for a sequence
consisting only of A, I, L, S and/or V).
79
Using a percent identity approach, both of these alignments
would be scored as 100% identical, the highest possible score, even
though the identity of the second pair is substantially more indicative
of homology than it is for the first pair. In fact, the significance of
100% identity to any given sequence depends upon the amino acid
composition of the sequence. The identity is much more predictive of
homology when the sequence has a large percentage of difficult to
substitute for amino acids (such as W and C) compared to a sequence
that is rich in easily substituted for amino acids (I, L , etc.).
Example 4 depicts the fifteen amino acid sequence of Example 3
aligned with a similar but non-identical sequence.
Example 4
R F Y QRH DV H M I D F Y Y
RY YQRH D L H I I DY FY
5 3 7 5 5 8 6 1 8 1 4 6 3 3 7 (72) 10/15 67% identity
Only ten of the fifteen pairings match, so the sequences are 67%
identical. In calculating the similarity score, the ten identical residues
are scored the same as in Example 3, while the scores for the other
five pairs are less, e.g., the F-Y pair generates a score of three, while
the F-F pair generates a score of six; the V-L pair generates a score of
one, while V-V generates a score of four. Note that in this example,
79. Id.; BIOINFORMATICS FOR GENETICISTS, supra note 13, Ch. 12.
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all of the substitutions are relatively conservative, with the substituted
amino acids sharing similar chemical and structural characteristics.
As a result, all of the scores are positive, albeit lower than the
corresponding identical pairing scores. The resulting score for the
alignment is seventy-two, necessarily less than the theoretical
maximum score of eighty-nine generated in Example 3, but still
higher than the score of sixty-eight generated for the 100% identical
sequences in Example 2.
Example 5 is another alignment of the sequence of Example 3
with a different 67% identical sequence.
Example 5
RF Y QRH DVHMI D FY Y
RY YQRH DLH I I DTKY
5 3 7 5 5 8 6 1 8 1 4 6-2-2 7 (62) 10/15 67% identity
In this case, two of the substitutions are non-conservative, i.e., F-
T and Y-K. Each of these substitutions generates a negative score
(-2). As a result, the similarity score for this alignment is only sixty-
two , substantially lower than the score of seventy-two generated in
Example 4 for another 67% identical alignment. This illustrates the
imprecision of percent identity as a predictor of homology. Because
percent identity does not take into account the chemical nature of the
substituted amino acids and the extent to which a change is
conservative, two alignments of the same length and percent identity
can generate very different similarity scores depending upon the
nature of the sequences and the substitutions. These differences in
score represent differences in the likelihood that the sequences are
homologous and share common functional/structural characteristics.
In this regard then, similarity score is a much better measure of
homology than percent identity, and as such provides better linkage
between structure and function for purposes of drafting valid patent
claims.
Example 6 is identical to the alignments of Examples 4 and 5,
except that lower sequence has a deletion at the positions
corresponding to amino acids thirteen and fourteen in the upper
sequence.
PROTEIN SIMILARITY SCORE
Example 6
RFYQRH DVHMI DFYY
RYYQRH DL H I I D- - Y
5 3 7 5 5 8 6 1 8 1 4 6(-13)7 (53)
In calculating a similarity score, deletions, i.e., gaps, are scored
using the formula y=a+bx, where y is the score for the gap, a is a gap
existence penalty, b is a gap extension penalty, and x is the length of
the gap (in this example the gap has a length of two, corresponding to
the two unpaired residues in the query sequence). The magnitude of
the gap penalties can be varied, in the same way that different scoring
matrices can be employed. In this article, a gap existence penalty of
-11 and gap extension penalty of -1 will be used. These are typical
values, and are the default penalties used in NCBI BLAST. In
Example 6, the two amino acid gap generates a score of -13. The
similarity score for the alignment is fifty-three, significantly lower
than for the 67% identity alignments that did not include any gap.
The lower score for the alignment of Example 6 compared to
Examples 4 and 5 reflects the biological significance of the insertion
of a gap in the alignment. From an evolutionary and functional
conservation standpoint, a gap in an alignment generally represents a
much more significant difference between sequences than a
corresponding amino acid substitution. The presence of a gap, no
matter how small, should be weighted much more heavily than a
simple substitution when analyzing aligned sequences for homology.
At the same time, once a gap has been introduced, the incremental
extension of the gap is only slightly more predictive of lack of
homology. In other words, the introduction of a short one or two
residue gap should result in a relatively large negative hit to the
similarity score.80 But most of the disruption is simply a consequence
of the insertion of a gap; the difference between a gap of two residues
and a gap of four residues is only minimal. The gap existence and
gap extension penalties normally employed account for this
phenomenon by imposing a large penalty (in this case -11) for the
introduction of the gap, but only a small penalty (in this case -1 per
residue) for the incremental extension of the gap.
Compare this treatment of deletions with the percent identity
approach. Most patent specifications that define "percent identity"
treat a deletion the same as any other mismatch. Thus, a one amino
80. See NCBI BLAST, supra note 74.
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acid deletion is penalized to the same extent as a conservative amino
acid substitution, and a ten amino acid deletion is penalized ten times
as much as a one amino acid deletion. This is clearly a gross
oversimplification, since a one amino acid deletion is predicted to be
much more disruptive to function than a conservative substitution, but
extension of the deletion to ten amino acids only marginally increases
the damaging effect of the initial introduction of the gap.
In summary, Examples 4-6 provide three alignments, all of
which would generate identical scores under a percent identity
approach. The similarity scores vary from seventy-two to sixty-three
to fifty-three, depending upon the nature of the non-identity. These
different scores reflect the fact that the sequences in Example 4 are
substantially more likely to be homologous than are those in Example
5, which in turn are more likely to be homologous than the sequences
of Example 6. If the intent in claiming a genus of related protein
sequences is that the sequences be homologous and/or share structural
and functional characteristics, the similarity score approach is clearly
superior to the percent identity approach.
Another advantage of the similarity score approach is that it
explicitly accounts for the lengths of the aligned sequences. A high
degree of conservation over a long stretch of sequence is more
predictive of homology than is the same degree of conservation over a
short segment. For example, it is intuitively obvious that 80%
identity between two 500 amino acid sequences is much more
predictive of homology than 80% identity of two, ten amino acid long
segments. However, while intuitively obvious, a simple percent
identity approach fails to account for this distinction. The similarity
score approach explicitly accounts for sequence length, rendering a
proportionately higher score to longer regions of conserved
sequence. 81 To illustrate, refer to Example 7, where the length of the
alignment in Example 4 is doubled simply by joining the aligned
sequences in tandem to a copy of itself. The percent identity remains
67%. The similarity score, on the other hand, doubles to 144,
reflecting the fact that it is much more likely that two thirty-amino-
acid sequences sharing this degree of similarity are homologous than
would be the case for the corresponding fifteen-amino-acid
sequences.
81. BIOINFORMATICS FOR GENETICISTS, supra note 13, Ch. 4.
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Example 7
RFYQRHDVHMI DFYYRFYQRHDVHMI DFYY
RYYQRHDLHI IDYFYRYYQRHDLHIIDYFY
537558618146337537558618146337 (144)20/30 67% identity
Because the similarity score approach more accurately accounts
for the functional impact of specific amino acid substitutions and gaps
in an alignment, it is particularly suited for predicting functional
synthetic analogs. As a consequence, a genus of related sequences as
defined by similarity score will include a substantially higher
percentage of functional variants compared to genus of comparable
size defined by percent identity. Assuming that some threshold
predictive accuracy is required of a sequence limitation, i.e., some
minimal fraction of a defined genus must be functional in order for
the claim to be valid, it follows that the similarity score approach
enables valid claims encompassing a substantially higher number of
functional analogs than could be achieved by percent identity. For the
patentee, this translates into expanded literal claim coverage.
Another advantage of the similarity score approach is that it is
more consistent with the approach used by scientists to compare
sequences. Typically, a scientist evaluating a sequence and looking
for homologs or functionally-related molecules will use a sequence
alignment tool such as BLAST. The output of a BLAST search is a
list of related sequences, ranked in order of similarity and including
scores that represent the likelihood that the sequences are related to
the query sequence.82 These scores are all derived from similarity
scores based on a substitution matrix and gap penalty.83 A similarity
score is a technically superior approach to sequence comparison, and
will be viewed by a biologist as a more rational approach to claiming
a protein genus than the percent identity approach.
B. Protein Claims Reciting Similarity Score
To employ similarity scores in the claiming of proteins, I
propose simply using a modified version of the percent identity claim
82. This is the standard alignment tool provided by the NCBI, which is the primary
public resource for molecular biology information in the U.S. See NCBI, at
http://www.ncbi.nlm.nih.gov (last visited Oct. 4, 2004).
83. For a more detailed explanation of BLAST scoring, see the documentation provided
at the NCBI BLAST website, at http://www.ncbi.nlm.nih.gov/BLAST (last visited May 25,
2004).
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format, substituting similarity score for the percent identity limitation.
For example:
An isolated polypeptide comprising an amino acid sequence that
when optimally aligned with SEQ ID NO: I will generate a
similarity score of at least X using the BLOSUM62 matrix, a gap
existence penalty of 11, and a gap extension penalty of 1, wherein
the polypeptide has Y functional activity.
The claim has a functional limitation to exclude non-functional
analogs and a similarity score limitation precisely delimiting the
scope of the claim. It also specifically recites the scoring matrix and
gap penalties; when using a similarity score approach to claiming it is
critical that these terms be explicitly defined, either in the claims
themselves or in the definition of similarity score provided in the
written description. The scoring matrix and gap penalties used in this
example are the NCBI BLAST defaults, and are probably the best
defaults to use in general claim drafting.84
The generation of an unambiguous score for two sequences
depends upon the optimal alignment being unambiguous. The term
"optimal alignment" should be defined simply as the alignment
(including the introduction of gaps in the sequences as necessary) that
results in the highest similarity score. Some issued patents provide
complex definitions of alignment that require the use of a computer-
implemented algorithm to determine optimal alignment. 85 This is not
necessary with the similarity score approach. Practically speaking, a
computer algorithm might be required in some cases to initially figure
out what the optimal alignment is (when the sequences are quite
divergent and/or when gaps must be introduced), but a computer is
not required to define optimal alignment or to determine whether an
accused sequence falls within the scope of the claim.
For example, during litigation a patentee would simply present to
the court an alignment of the claim's reference sequence and the
accused sequence (which would likely have been generated using a
computer) and tabulate the similarity score (which can be done
84. In some cases, a more sophisticated approach might involve using alternative scoring
matrices and/or gap penalties that are more biologically relevant for the particular genus of
claimed sequences. In principle, this would provide some (likely marginal) improvement in the
accuracy of the similarity score in predicting functional variants. However, most practitioners
would probably simply employ the suggested default parameters, which are on average the best
for typical sequences; any predictive improvement achieved by optimizing the scoring system
would likely be minimal compared to the substantial improvement that results simply in going
from percent identity to a similarity score approach.
85. See e.g., U.S. Patent No. 6,605,450, claim I (issued Aug. 12, 2003).
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manually as described above). If the score exceeds the score recited
in the claims, the sequence literally infringes (assuming that any
functional or other limitations are also satisfied). The result is
unambiguous, and the accused infringer will have no basis for arguing
for a different alignment because by definition the correct alignment
is the one that yields the highest score. Any alternative alignment
proposed by the accused infringer would either generate a lower
score, and hence by definition would not be the optimal alignment, or
a score that is equal to or greater than that generated by patentee's
alignment, in which case the accused sequence still falls within the
scope of the claim.
A critical issue when drafting a similarity score claim is the
determination of an appropriate threshold similarity score (X in the
above example). Of course, the score must be less than the theoretical
maximum score (the score generated by aligning the sequence with
itself) if it is to encompass any sequences beyond the recited
sequence. At the same time, the score must be high enough to satisfy
the requirements of novelty and nonobviousness, as well as the
enablement and written description requirements.
With regard to novelty and nonobviousness, a similar sequence
in the prior art might impose a lower limit on the threshold score,
since the score would presumably have to be high enough to at least
exclude the prior art molecule. 86 In principle, it should also be high
enough to distinguish any variants that might be considered obvious
in view of the prior art sequence. For example, a threshold that
defined a genus so broadly that it would encompass single point
mutants of a prior art sequence might be considered obvious in light
of that prior art sequence. There is little guidance from the courts in
this regard, and the determination would likely depend upon the
specific sequences in question. The practitioner drafting a claim in
this situation would have to use judgment in assessing the distance the
genus needs to be from the closest prior art sequence. Of course, a
series of dependent claims with increasing threshold scores could be
used as insurance against a claim being found obvious for
encompassing a genus that is too close to the prior art.
The other limitation on claim breadth is written description and
enablement, in particular the requirement of some correlation between
structure and predicted function. A determination has to be made as
to how high the threshold score must be in order for it to be
sufficiently predictive of homology and/or conserved function to
86. See 35 U.S.C. §§ 102-103 (2004).
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support a valid claim. Note that while this determination is somewhat
speculative, particularly in view of the scant guidance the courts have
provided with respect to the required degree of predicitivity, the need
to make such a determination is not new. At least implicitly, the same
determination has to be made with percent identity claims, i.e., the
Patent Office will only allow percent identity limitations that it
determines to be sufficiently predictive of homology. 7 The only
difference is that similarity score is a more accurate predictor; for
claimed sequence genuses of comparable size the validity of the
similarity score is on much more solid ground.
One approach to selecting an appropriate threshold score would
be to identify an allowable percent identity limitation and then use
that number to calculate a corresponding similarity score. Take, for
example, a case where one is claiming a particular amino acid
sequence, and assume that an 80% identity limitation would be high
enough to satisfy the enablement and written description requirement.
One could simply calculate a similarity score that corresponds to an
80% identical sequence and use that similarity score as a claim
limitation.
Of course, the similarity score can vary dramatically between
different 80% identical pairings, depending upon the nature of the
mismatches; conservative substitutions will yield relatively high
similarity scores, while nonconservative substitutions and
insertions/deletions will result in much lower similarity scores. This
is illustrated in Examples 8 and 9, which depict conservative and
nonconservative 80% identity alignments, respectively.
Example 8
RFWQRHDVHMI DFYYAWYQRHSVHC I DFAY
RFWQRHDIHMLDFYYSWYQRHAVHCLDFSY (171)24/30 80% identity
Both alignments share the same upper sequence, which would
yield a theoretical maximum similarity score of 185 when aligned
with itself.
Example 9
RFWQRHDVHMIDFYYAWYQRHSVHCI DFAY
RFNQRVDVCMIDFYYAKYQRHSVIPIDFAY (111)24/30 80% identity
87. See Synopsis ofApplication of Written Description Guidelines, supra note 41, at 46.
2004] PROTEIN SIMILARITY SCORE 85
The conservative substitutions of Example 8 result in a score of
171, while nonconservative substitutions of Example 9 drop the score
all the way down to 111. In fact, the score could have been
substantially lower than 111 if gaps were introduced into the
alignment. One drafting claims with an eye toward maximizing claim
scope would prefer to recite a similarity score limitation
corresponding to nonconservative substitutions, e.g., 111. Logically,
this limitation should be allowable since it is a biologically-based
measure of the functional similarity of the 80% identical sequences,
and we have assumed that the 80% identity limitation would have
been acceptable under the current scheme. However, a similarity
score limitation of 111 is much broader than an 80% identity
limitation, since it would encompass alignments sharing much lower
percent identity but more conservative substitutions. This is
illustrated in Example 10, where the upper sequence from the
Examples 8 and 9 alignments is aligned with a sequence sharing only
27% identity, but where the substitutions are conservative and as a
result, the similarity score is relatively high at 115.
Example 10
RFWQRHDVHM IDFYYAWYQRHSVHC I DFAY
KYWEKHEIHLLNYFYSWFEQHAIHCLEYSF (115)8/30 27% identity
This nicely illustrates the ability of the similarity score approach
to capture functionally similar sequences that are relatively distant in
terms of percent identity. It also illustrates an inherent weakness to
the percent identity approach, in that the biological significance of a
given percent identity limitation will vary dramatically depending
upon the nature of the mismatches.
Alternatively, instead of basing a similarity score claim
limitation upon a corresponding percent identity claim limitation, an
appropriate threshold similarity score could be arrived at de novo
based upon the likelihood that it represents true homology and/or
conserved function. As described in more detail below, the BLAST
program can convert similarity scores into "expectation values" (i.e.,
"E-values"), which are a measure of the likelihood that two similar
sequences are truly homologous. Thus, one could use this type of
calculation to assess how predictive a given threshold score is of
homology for a particular reference sequence of interest, and draft
claims accordingly.
86 SANTA CLARA COMPUTER & HIGH TECH. L.J. [Vol. 21
Not only is the similarity score approach technically superior to
percent identity, similarity scores are unambiguous and easily
determined, either manually or with the aid of a computer. There is a
perception among some that similarity scores (e.g., BLAST scores)
are generated by arcane and complex algorithms that can only be
understood by one with a fairly sophisticated understanding of
computer science or bioinformatics, and that the scores can only be
practically calculated by means of a computer. As shown above, a
similarity score for aligned sequences can be calculated manually
with simple arithmetic, merely by applying a given scoring matrix to
the aligned sequences (and if appropriate, employing a gap penalty).
While the science underlying the generation of substitution matrices
and the determination of appropriate gap penalties is fairly
sophisticated, once the matrix and gap penalties have been defined,
any person able to do simple arithmetic can readily calculate a score
for a pair of aligned sequences of moderate length, i.e., on the order
of hundreds of amino acids, the length of a typical claimed protein
sequence. Thus, it would be straightforward for a judge or jury to
evaluate an alignment of the sequences recited in a claim and an
allegedly infringing sequence and determine whether or not it falls
within the literal scope of the claim. This enhances the transparency
of claim interpretation, since one need not rely on a computerized
"black box" to determine the score, and ultimately to determine
whether an accused protein sequence literally infringes.
IV. USING THE BLAST PROGRAM WITH SIMILARITY SCORE CLAIMS
While it is advantageous that similarity scores can be calculated
manually, in practice one would normally employ a computer to align
and score similar sequences, e.g., when drafting claims, assessing the
validity of claims, or determining whether a particular sequence of
interest falls within the scope of the claims. A number of computer
programs are available that will fulfill this function, including
BLAST, FAST-All (FASTA) and various implementations of the
Smith-Waterman algorithm.88 To illustrate, I will focus on the
BLAST program at the NCBI website ("BLAST"), since it is freely
88. See, e.g., NCBI BLAST, supra note 74; FASTA Protein Database Query, European
Bioinformatics Institute, at http://www.ebi.ac.uk/fasta33/ (last visited Sept. 25, 2004); MPsrch
Submission Form (Smith-Waterman algorithm), European Bioinformatics Institute, at
http://www.ebi.ac.uk/MPsrch (last visited Sept. 25, 2004),
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available via the Internet and configured to search the most extensive
databases of protein sequences available in the public domain.89
A. An Overview of BLAST
When using BLAST to calculate a similarity score for two
sequences, or to draft or analyze a similarity score claim, it is
important that various adjustable parameters in the program be
properly set. Bear in mind that the primary intended function of
BLAST is to address biological questions, not to calculate similarity
scores for the purpose of claim drafting. BLAST employs a variety of
refinements to adjust a "raw" similarity score (i.e., a score based only
on substitution matrix and gap penalties), thereby fine-tuning the
score to more accurately predict the evolutionary significance of the
similarity between aligned sequences. While these refinements result
in a more biologically relevant score, in the context of patent claiming
they introduce unnecessary complexity, and in some cases ambiguity,
to the score. In my view, this increased complexity and ambiguity is
not justified by the relatively slight improvement in biological
relevance. Therefore, my recommendation is not to use the
refinements in drafting protein claims, but instead to use only the raw
score.
For example, BLAST offers the option of using "composition-
based statistics." In fact, it is used in the default setting of the
program. Composition-based statistics employs a scaling procedure
that in effect uses a slightly different scoring system for each
sequence in the database being searched. 90  Because a different
scoring system is used, a raw score (or "raw S score") obtained with
this feature turned on will be slightly different than the raw score that
would be obtained simply by using the scoring matrix and gap
penalties. While from a biologist's perspective, composition-based
scaling is of value since it will somewhat improve the accuracy of the
score, it is undesirable in the context of patent claims since it renders
89. The Basic Local Alignment Search Tool (BLAST) program is commonly used by
scientists to perform sequence alignments of protein sequences. The typical user is a researcher
with a protein sequence of interest, i.e., a query sequence. The scientist submits the query
sequence and chooses a protein database, and the BLAST algorithm will search that database for
similar sequences, based on similarity score. The output is a ranked listing of similar sequences
exceeding some certain threshold score. Along with the similarity score, the program also
provides alignments of all the sequences with the query sequence. Sequence alignments provide
a powerful way to compare novel sequences with previously characterized genes. Both
functional and evolutionary information can be inferred from well designed queries and
alignments.
90. See NCBI BLAST, supra note 74.
2004]
88 SANTA CLARA COMPUTER & HIGH TECH. L... [Vol. 21
the scores unstable. This instability arises because the scaling
procedure takes into account all of the sequences in the database, and
the sequence databases are highly dynamic, constantly changing as
new sequence information is submitted by researchers. 91 As a result,
scores obtained for identical sequences as calculated with
composition-based statistics turned on will vary with time. 92 Clearly
this is undesirable from a patenting standpoint, which requires a score
that is stable and independent of the nature of any particular database.
Turning off the composition-based statistics results in a stable score
that is based solely on the scoring matrix and gap penalties.
Another default BLAST option that should be disabled when
calculating a similarity score is the "low complexity filter." The low
complexity filter masks off sections of the query sequence having low
compositional complexity, i.e., sections of the sequence that are
predominantly made up of one or a few amino acids. 93 Common
examples are acidic-, basic-, and proline-rich regions of a protein
sequence. The filtering can eliminate statistically significant, but
biologically uninteresting reports from the BLAST output, and hence,
is a useful feature for most biologically relevant searches.94 However,
such filtering will alter the raw score by ignoring certain amino acid
pairings. Therefore, in determining a similarity score for patent
purposes, all filters, including the low complexity filter, should be
disabled.95
It is also important when using BLAST to understand that each
alignment generates several different scores, all ultimately derived
from the raw alignment score. One needs to be able to distinguish
between the scores, and identify the correct "raw score" for claiming
purposes. For example, consider an excerpt from an actual BLAST
output shown in Figure 2. Just above the alignment are two scores-a
"raw alignment score," or "S" (in parenthesis), and a "bit score," or
"S"'. In this example, S is 952 and S' is 371 bits. The S score is the
"similarity score" of interest to us, calculated based solely on scoring
91. See GenBank Overview, NCB1, at
http://www.ncbi.nih.gov/Genbank/GenbankOverview.html (last visited Sept. 25, 2004).
92. This will be observed by anyone who does a BLAST search of a particular sequence
(with composition based statistics turned on), keeps the results, and then re-runs the exact same
search a month later. They will likely find that, as a result of this scaling feature and additions
to the database over the course of the month, the raw score for alignment of the exact same
sequences will have changed.
93. See NCBI BLAST, supra note 74.
94. See id.
95. There are a number of other optional settings. For detailed explanations of all these
settings, see NCBI BLAST, supra note 74.
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matrix and gap penalty. The bit score (S') is a normalized score
derived from the raw alignment score S in a manner which takes into
account the statistical properties of the scoring system. 96 Because bit
scores have been normalized with respect to the scoring system, they
can be used to compare alignment scores from different searches that
were based on different scoring systems. Thus, for the biologist, the
advantage of using the bit score instead of the raw score comes when
one is comparing the biological relevance of scores obtained using a
different scoring system (i.e., a different scoring matrix and/or gap
penalty). This is not an issue for patent claiming purposes. The
disadvantage of using a bit score for claiming purposes is that it
introduces unnecessary complexity and ambiguity into the score.97
96. To convert a raw score S into a normalized score S' expressed in bits, one uses the
formula S' = (lambda*S - In K)/(ln 2), where lambda and K are parameters dependent upon the
scoring system (substitution matrix and gap costs) employed. For a detailed explanation of bit
scores, see Lambda Ratio, NCBI, at
http://www.ncbi.nlm.nih.gov/BLAST/matrix-info.html#ambda (last visited May 25, 2004).
97. Id.
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Figure 2
98
>gi139139851spQ442871LAMB AERSA Maltoporin precursor (Maltose-inducible porin)
gi)5412321pir S37779 porin precursor, maltose-inducible - Aeromonas salmonicida
gi1398210lembICAA49223. I maltose-inducible porin [Aeromonas salmonicida]
Length = 445
Score = 371 bits (952), Expect = e-101
Identities = 200/447 (44%), Positives = 271/447 (60%), Gaps = 32/447 (7%)
Query: 1 MKTSLRTLSVALAAALVSPSVLAIEKIDFHGYMRAGVGVSSDG ---- GLAEWQKTMVGRL 56
MK ++ + AAL S + A+ DFHGY R+GVGVS+DG GL++ K VGRL
Sbjct: 3 MKAKWLPIAAGVTAALASQAAFAV---DFHGYFRSGVGVSTDGSMQTGLSDNAKQKVGRL 59
Query: 57 GNESDTYGEIGLGAEVYKKEDVSFYLDSMVSMLSDGSNDSETTIG --------------- 101
GNE+DTYGEI LG+EV+ K+ +FY+DSMV+M S+GSND E+T
Sbjct: 60 GNEADTYGEIQLGSEVFNKDGKTFYVDSMVAMTSNGSNDWESTESKFQCTSANGTALDGC 119
Query: 102 ---DDAQFGLRQLNLQIKGLIPGDKEAVIWGGKRYYQRHDLHTIDTKYWNISGSGAGIEN 158
+DA F LRQ N+Q KGL+ EA +W GKRYYQRHD+HI D YWNISG GAGIE
Sbjct: 120 ENKEDATFALRQFNVQAKGLLGFAPEATLWAGKRYYQRHDVHISDFYYWNISGRGAGIEG 179
Query: 159 YTVGPGAVSVAWVRGDANDVDTRITGDSDVNINYIDVRYAGFKPWAGSWTEVGIDYAMPN 218
GPG VS AWVR D + + T + ++N+N +D+RYAG W EVG+DYA+ N
Sbjct: 180 IQAGPGKVSFAWVRNDRSGTNVDGTYNDEMNVNTLDLRYAGIPLWQDGSLEVGVDYAIAN 239
Query: 219 PTKQQKEYGGLY--DADNAVMLTGEISQDMFGGYNKLVLQYANKGLAQNMISQGG-GWYD 275
P+ QK+ +A + VMLT E++Q + GG+NK VLQY +G ++ G WY
Sbjct: 240 PSDAQKDSANAQYKNAKDGVMLTAELTQGILGGFNKTVLQYGTEGYSKTFAFWGDRSWYG 299
Query: 276 MSHKTDEAKGYVINTGLIPITDKFSFNHVLTWGSANDITEYTDKTNLISLVGRAQYQFT 335
K D A G+R+IN G+IP+± . H L +G ND+ + DK +S+V R Y++
Sbjct: 300 AEAK-DGADGFRIINHGVIPMGNSWEMGHQLVYGVGNDMWDTNDKWETMSVVARPMYKWD 358
Query: 336 QYVKAIGEVGGFYQKDTYHNGSNYKQGGEKYTIALGLAEGPDFLSRPELRVFASYLNDSE 395
+ + I E G F K+ NG++ + G K T+A + G F +RPE+RVFASYL +
Sbjct: 359 DFNKTIFEGGYFKDKNKSTNGTSEEDAGYKLTLAQAWSAGSSFWARPEIRVFASYLAQDK 418
Query: 396 --- NGKPFEDGTSNDTWNFGVQVEAWW 419
G F +GT++DTWNFGVQ EAWW
Sbjct: 419 KEMKGNAFNNGTADDTWNFGVQAEAWW 445
98. Figure 2 is an excerpt from the output of a BLASTP search conducted on the NCBI
website, supra note 74, on May 25, 2004.
PROTEIN SIMILARITY SCORE
Along with the raw and bit scores, the "expectation," or "E
value" is provided. For example, in Figure 2 the E value is e-1°1. The
E value is a statistical measure derived from the score, and represents
the number of different alignments with scores equivalent to or better
than S that are expected to occur by chance in a search of a sequence
of the size of the query sequence in the database searched. 99 The
significance of this value is that in a database containing a large
number of sequences, by random chance there are going to be some
sequences that have a certain degree of similarity with the query
sequence. The higher the S score of an alignment, however, the less
likely it is that the alignment is the result of chance similarity and the
more likely that it represents true homology. The formula used by
BLAST to calculate E is E=mN2 -s', where S' is the bit score and "m"
and "N" are, respectively, the lengths of the query sequences and the
total length of the database in residues. °00 The lower the E value, the
more significant the score, i.e., the higher the likelihood that this
indeed represents an alignment of homologous sequences as opposed
to a chance similarity appearing in two sequences of unrelated
origin. 01
The E value is typically the score that a biologist reviewing a
BLAST output would be most interested in, since it provides the best
intuitive measure of how close the aligned sequences are to one
another, e.g., an E value of 10-6 represents that there is only a one in a
million chance that an alignment with that high of a score would be
achieved for the given query sequence and database searched, i.e.,
there is a very high degree of confidence that this alignment reflects
true homology. On the other hand, an E value of ten represents that
just by chance ten alignments with a score of that magnitude would be
expected to be found by the search. In this case, there is much less
confidence that the aligned sequences are actually related.
While the E value provides the best measure of the likelihood of
homology between two sequences, it is not appropriate for use as a
substitute for percent identity in claiming proteins. Not only does it
have the ambiguity and undue complexity associated with S', but the
99. Samuel Karlin & Stephen F. Altschul, Methods for Assessing the Statistical
Significance of Molecular Sequence Features by Using General Scoring Schemes, 87 PROC.
NAT'L ACAD. Sci. USA 2264 (1990), available at
http://www.pnas.org/cgi/reprint/87/6/2264.pdf (last visited Oct. 25, 2004).
100. The database is treated as a single long sequence of N residues. Note that the E value
incorporates the raw score (S), the statistical nature of the scoring system (K and lambda), and
the size of the query and database (m and N).
101. See NCBI BLAST, supra note 74.
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value of E will vary dramatically depending upon the size of the
database searched (N in the equation). Thus, the value only has
meaning in the context of a search of a particular database. BLAST
offers the option of searching any of six different databases, each of
which has a different size, depending upon the number of sequences
in the database and the length of the sequences. 10 2 The larger the
database searched, the larger the value of E, and hence the greater the
likelihood that the scoring alignment is purely the result of chance.
B. Determining Infringement of Similarity Score Claims
Suppose one would like to know whether a sequence of interest
(a "query sequence") falls within the scope of a similarity score claim.
It would be necessary to determine the similarity score for an optimal
alignment of the claim's reference sequence and the query sequence.
A simple way to calculate this similarity score would be to use the
BLAST 2 Sequences tool provided on the NCBI website.10 3 To do so,
a user simply inputs the reference and query sequences as the
sequences to be scored (e.g., by pasting in the sequences, with the
amino acids represented by their single letter symbols), chooses the
desired scoring matrix and gap penalties (those suggested herein, i.e.,
the BLOSUM62 matrix and gap existence and extension penalties of
11 and 1 are the current defaults), turns off all filters, and clicks the
alignment button. The program will optimally align the sequences
and provide the similarity score. As described above, BLAST 2
reports three scores, the raw S score being the similarity score. For
example, if the sequences of Example 4 are inputted, the score is
reported as "Score = 32.3 bits (72), Expect = 2.3." The similarity
score (raw score) is in parentheses (72). If the similarity score
exceeds that recited in the claim, the query sequence falls within the
literal scope of the claim.
C. Examining or Analyzing Similarity Score Claims
As another example, a patent examiner could use BLAST to
analyze a similarity score claim with respect to the prior art.1°4 The
NCBI BLAST tool allows one to search what is referred to as the "nr"
database. This is a non-redundant protein sequence database
102. See id.
103. See NCBI BLAST2 Sequences, NCBI, at
http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html (last visited May 25, 2004).
104. 35 U.S.C. § 131 (2004) provides the statutory authority for the PTO to examine
patent applications.
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compiled from a variety of sources, and is the largest and most
complete single database of protein sequences in the public domain.1
0 5
In particular, to run a BLAST search on a reference sequence to
determine if any public domain sequences fall within the similarity
score limitation, one can access the BLAST program at the NCBI
website.10 6 The "protein-protein BLAST ("blastp")" should then be
selected, which will pull up the protein-protein BLAST page (the
most basic version of BLAST for comparing polypeptide sequences).
There the user is presented with a number of fields to be completed.
This discussion will focus only on those fields that are relevant for
our purposes; many will simply be left at their default setting. One
important field is "Search"; this is where the claim's reference
sequences (the sequence can simply be copied and pasted in) should
be entered.
Next, the proper database to search must be chosen. There are
currently six databases to choose from; we will stay with the default
"nr" database, as described above.
Moving down to the "Options for Advanced Blasting" section of
the page, the "composition-based statistics" and the "low complexity
filter," should be turned off. These are on by default, but for the
reasons previously discussed, should be disabled when determining a
similarity score.
The program allows the user to choose the scoring matrix and
gap costs. We will use the default settings of BLOSUM62, gap
existence penalty of 11 and gap extension penalty of 1. Of course,
one could decide to use a different matrix and/or gap penalties in a
similarity score claim, and in that case, these settings should be
adjusted.
Other parameters (e.g., the threshold level for expectation values,
etc.) will not affect how the search algorithm is implemented, and
should normally be left in their default settings.
As an example, consider an artificial sequence concocted by
taking the sequence of maltoporin precursor protein and randomly
changing 102 of its amino acid residues.'0 7 The full length of the
sequence is 419 amino acids. Therefore, this artificial mutant retains
105. There is no single database that contains all sequences that might be considered prior
art, but the nr database, or for that matter any database that the PTO would like to search, can be
searched using the BLAST tool.
106. See NCBI BLAST, supra note 74.
107. See supra note 98. This sequence is not intended to have any biological relevance,
but is used merely to exemplify the mechanical operation of the BLAST tool and its application
to the similarity score approach to claiming proteins.
2004]
94 SANTA CLARA COMPUTER & HIGH TECH. L.J. [Vol. 21
about 75% identity to the original sequence. To run a BLAST search,
access the blastp page, paste the sequence into the search field, select
the nr database and adjust the default settings as indicated above, and
then submit the query. After the query has run, a BLAST output is
given.
Excerpts from the BLAST output obtained for this query on May
25, 2004 are presented in Figures 3 and 4. Figure 3 shows the ranked
listing of top scoring related sequences. The top scoring sequence
(gil61211581reflNP_404471.11) is the native maltoporin precursor
sequence. Thus, even after changing 25% of the amino acid
positions, the most similar sequence is still the starting sequence.
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Figure 3
Related Structures
Score E
Sequences producing significant alignments: (bits) Value
giIl6121158refINP_404471.11 maltoporin [Yersinia pestis) > ... 627 e-178
gi1221271111refINP_670534.11 putative outer membrane protei ... 627 e-178
gil454432841refINP_ 994823.11 maltoporin [Yersinia pestis bi... 624 e-177
gi(3913985(sp(Q44287LAMB_AERSA Maltoporin precursor (Malto... 272 le-71
gil398211embICAA49224.11 maltose-inducible porin [Aeromona ... 271 le-71
gil31340212IsplQSKKHIBLMB2_AERHY Maltoporin precursor (Malt... 263 5e-69
giI313402l1ispIQ8KKH01LMB1 AERHY Maltoporin precursor (Malt... 261 
2
e-68
gi(30793638(gb(AAP40342.11 Omp48 protein precursor (Aeromon ... 254 2e-66
gif28901499(ref(NP 801154.1) maltose-inducible porin [Vibri ... 245 le-63
gl46913859(emb(CAG20641.1i hypothetical maltoporin [Photob... 226 9e-58
gill156017811ref(NP 233412.11 maltoporin [Vibrio cholerae 01... 148 2e-34
gi139142291spiQ56652(LAMBVIBCH Maltoporin precursor (Malto ... 146 9e-34
qi(32035629(ref(ZP 00135540.1) COG4580: Maltoporin (phage 1... 137 3e-31
gi)161238491refNP 407162.11 maltoporin (Yersinia pestis] > ... 132 le-29
gi1454428281refINP 994367.11 maltoporin (Yersinia pestis bi ... 132 le-29
gii221239531ref(NP_667376.11 maltose high-affinity receptor... 132 le-29
gi12801231pirl)A
60
1
7
7 LamB maltoporin protein precursor - S... 131 3e-29
gil167674811refINP_463096.11 maltoporin precursor (Salmonel. .. 130 4e-29
gi1167629121refINP_458529.11 maltoporin precursor [Salmonel ... 130 
7
e-29
giI20983961pdbi2MPRIA Chain A, Maltoporin From Salmonella T ... 129 9e-29
giil941972IpdbIlMPRIA Chain A, Maltoporin From Salmonella T ... 128 3e-28
gi1241153731refINP_709883.11 phage lambda receptor protein;... 127 6e-28
gi(161318621refJNP_418460.1) phage lambda receptor protein ... 127 6e-28
gi1300646271refINP_838798.11 maltose high-affinity receptor... 127 6e-28
gi158046291ref(NP_290670.11 phage lambda receptor protein;... 127 6e-28
gi(262508181ref1NP 756858.11 Maltoporin precursor [Escheric ... 127 6e-28
gi(3963711gbiAAC43l30.11 phage lambda receptor protein 125 le-27
gi(400158(spjP31242(LAMB KLEPN Maltoporin precursor (Maltos... 125 2e-27
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Figure 4
Alignments
>giI16121158IrefINP 404471.1) maltoporin [Yersinia pestis]
gi1201386361splQ8ZHP0ILMB2_YERPE Maltoporin precursor 2 (Maltose-inducible
porin)
gil25298933(pirl1AF0104 maltoporin [imported] - Yersinia pestis (strain
C092)
gil159789241emb(CAC89697.11 maltoporin [Yersinia pestis C092]
Length = 419
Score = 627 bits (1616), Expect = e-178
Identities = 317/419 (75%), Positives = 339/419 (80%)
Query: 1 MKVSLKTGTLVAAASLVGPSGPAIDKHIFHMYARSLITVCKDGGLAEWDKTMVERLGNES 60
MK SL+T ++ AA+LV PS AI+K FH Y R+ + V DGGLAEW KTMV RLGNES
Sbj ct: 1 MKTSLRTLSVALAAALVSPSVLAIEKIDFHGYMRAGVGVSSDGGLAEWQKTMVGRLGNES 60
Query: 61 DTYGFIHLGAEKYKQHDVSYYGDSMVSTLGDGSNDSPWTIGNQAQFGLRQLNLQPKGEIP 120
DTYG I LGAE YK+ DVS+Y DSMVS L DGSNDS TIG+ AQFGLRQLNLQ KG IP
Sbjct: 61 DTYGEIGLGAEVYKKEDVSFYLDSMVSMLSDGSNDSETTIGDDAQFGLRQLNLQIKGLIP 120
Query: 121 GDKEAVRSGGSRYYQRHDLHILCTKYWNISGSGAGIENYTVGPGAVSVAWVRGDANDVDT 180
GDKEAV GG RYYQRHDLHI+ TKYWNISGSGAGIENYTVGPGAVSVAWVRGDANDVDT
Sbjct: 121 GDKEAVIWGGKRYYQRHDLHIIDTKYWNISGSGAGIENYTVGPGAVSVAWVRGDANDVDT 180
Query: 181 RITGDSDVNINYVDVRYAGFCSWAGSWTEVGIDYAMIAGHKQMKVYGEQFDVINAVMLTG 240
RITGDSDVNINY+DVRYAGF WAGSWTEVGIDYAM KQ K YG +D NAVMLTG
Sbjct: 181 RITGDSDVNINYIDVRYAGFKPWAGSWTEVGIDYAMPNPTKQQKEYGGLYDADNAVMLTG 240
Query: 241 TISQDMFGNYNKDSTQYANKGLAQPEIQQGGAWYDMVHKHDNPKGWRVLNTGLFPASDKF 300
ISQDMFG YNK QYANKGLAQ I QGG WYDM HK D KG+RV+NTGL P +DKF
Sbjct: 241 EISQDMFGGYNKLVLQYANKGLAQNMISQGGGWYDMWHKTDEAKGYRVINTGLIPITDKF 300
Query: 301 TFNHVLTGWEENDITEYQDKVQVISLVGRMQYQFSQYVRAIGEVGGFYQKDTYSNLSNFI 360
+FNHVLT NDITEY DK +ISLVGR QYQF+QYVPAIGEVGGFYQKDTY N SN+
Sbjct: 301 SFNHVLTWGSANDITEYTDKTNLISLVGRAQYQFTQYVRAIGEVGGFYQKDTYHNGSNYK 360
Query: 361 NAGEKYTIALGLAEGMDFTSRPELRVFASYLQESENGYGFEMGTSNQTWNFGVQVESWW 419
GEKYTIALGLAEG DF SRPELRVFASYL +SENG FE GTSN TWNFGVQVE+WW
Sbjct: 361 QGGEKYTIALGLAEGPDFLSRPELRVFASYLNDSENGKPFEDGTSNDTWNFGVQVEAWW 419
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Figure 4 is the alignment between the query sequence and native
maltoporin precursor. The similarity score is 1,616, i.e., the "raw
score" appearing in parenthesis after the score in bits. Hence, the
native maltoporin precursor sequence would be encompassed by a
claim reciting this query sequence as a reference sequence and a
similarity score limitation less than or equal to 1,616. If that were the
case, the examiner would need to investigate this and any other
sequences that fall within the limitation to determine whether they are
prior art, e.g., whether the putative prior art sequence was actually
published prior to the invention of the claimed sequence. 108 If the
sequence is in the prior art and there are no other claim limitations to
distinguish it, e.g., a functional limitation that excludes the native
maltoporin precursor sequence, then the examiner would generally
reject the claim as anticipated. The applicant might then respond by
amending the claims to increase the similarity score threshold to
avoid the prior art sequences.
This same sort of analysis could also be conducted to assess the
validity of issued claims. For example, a third-party interested in
evaluating the validity of the claim could run the same BLAST search
post-issuance. If a sequence that falls within the recited similarity
score range is found to exist in the prior art, this might form the basis
of an argument that the claim is anticipated, invalid and should not
have been issued by the Patent Office. This analysis, of course, might
depend upon a determination of whether the prior art sequence
possesses any functional limitation recited in the claims.
D. Drafting Similarity Score Claims
Suppose that an inventor has discovered what is believed to be a
novel, patentable protein sequence and wishes to use it as a basis for a
patent claim directed to a genus of similar protein sequences, using
the similarity score approach. A first step might be to submit the
sequence as a BLAST query against the nr database in order to (1)
confirm that the sequence is indeed novel, (2) identify the closest
similar sequences in the public domain, and (3) to obtain similarity
score for the alignment of the query sequence with similar public
domain sequences.
108. This information can usually be gleaned from the GenBank record for the sequence,
which contains information regarding the date when the sequence was first posted, publication
information, etc. Conveniently, the GenBank records of sequences are normally hyperlinked to
the identifier as it appears in the BLAST output. See GenBank Overview, supra note 91.
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To illustrate, let us consider the same artificial sequence
analyzed above, but this time imagine it as a novel sequence one is
interested in patenting. Again, we would find that the top scoring
sequence is the native maltoporin precursor sequence from which the
query sequence was derived. The similarity score, i.e., the "raw
score," is 1,616. Depending upon the rigor with which we wish to
search the prior art, we might decide to try the BLAST against other
databases to which we might have access. For the purposes of this
illustration, we will assume we are satisfied with the result of
searching the nr database.
Because the sequence appears to be novel, with no closely
similar molecules appearing in the public domain, it appears that prior
art is not a bar to patenting the molecule. In this scenario, we have
identified the most similar sequence as being the maltoporin
precursor. In light of the relatively high similarity between the
sequences, we might be able to infer something about the function of
our novel sequence, i.e., if the novel sequence was isolated from a
natural source, the high similarity score with maltoporin precursor
indicates likely homology and conserved function.
Of course, the scope of a genus claim encompassing the
sequence can be limited by the proximity of the prior art. In this case,
the closest prior art sequence has a raw score of 1,616. Thus, any
claimed genus defined using the novel sequence as the reference
sequence and a similarity score limitation would probably need to
recite a score higher than 1,616 to avoid reading on the prior art
sequence.
In determining the magnitude of the similarity score threshold
for the claim, it is useful to know the theoretical maximum score for
an alignment with the novel sequence. This would be the score for
alignment of the sequence with the identical sequence, i.e., 100%
identity. A convenient way to determine this score is by means of the
BLAST 2 Sequences (BL2S) tool described above, i.e., by simply
aligning the novel sequence with itself. In this example, the
calculated raw score S is 2,258, which represents the maximum score
for any alignment with this sequence.
In drafting a claim, the inventor in this scenario would generally
base his claim on a similarity score limitation lying somewhere
between 1,616 (the score of the closest prior art sequence) and 2,258
(the theoretical maximum score). A score of 1,617 would provide
optimal scope of coverage from the patentee's point of view, but it is
questionable whether the Patent Office or the courts would allow such
broad coverage. The claim would presumably not be anticipated, but
PROTEIN SIMILARITY SCORE
might be found obvious for claiming a large number of sequences that
are very close to the prior art sequence.1 9 The value ultimately
allowed by the PTO should lie somewhere between 1,617 and 2,258,
and would need to be sufficiently high to satisfy the requirements of
§ 112. As discussed above, an appropriate threshold value can be
derived from an allowable percent identity limitation, and/or could be
informed by converting a proposed similarity score limitation to a
corresponding E value to assess the number's biological significance.
V. CONCLUSION
For a variety of reasons, the similarity score approach represents
a more rational and scientific basis to claiming a genus of related
proteins compared to the current practice based on percent identity.
While this approach might meet initial resistance from some patent
examiners or practitioners unfamiliar with the concept of similarity
score, by educating these individuals to the advantages of similarity
score it should be possible to convince them to accept this as a valid,
and indeed superior, alternative to percent identity claiming. The
widespread adoption of this approach would result in more effective
claim coverage for the patentee, with a greater likelihood that the
claims will withstand a challenge to validity during litigation.
109. For example, a claim reciting a threshold score of 1,617 would encompass many
point mutants of the maltorporin precursor sequence, including any mutant where any one of the
102 amino acid differences is substituted by the corresponding residue in the claimed reference
sequence.
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